Scientists at The Wistar Institute and Stanford University Report Encouraging Results on First-In-Human Clinical Trial for an Investigational Drug to Treat Epstein-Barr Virus Cancer
January 21, 2025
January 21, 2025
PHILADELPHIA, Pennsylvania, Jan. 21 (TNSjou) -- The Wistar Institute issued the following news release:
In newly reported clinical trial results, The Wistar Institute and Stanford University have successfully tested an investigational drug for the treatment of Epstein-Barr Virus (EBV)-positive nasopharyngeal cancer (NPC) in humans. The drug VK-2019 was tested in a first-in-human clinical trial by a research team led by Wistar research associate professor Troy Messick, Ph.D., and Sta . . .
In newly reported clinical trial results, The Wistar Institute and Stanford University have successfully tested an investigational drug for the treatment of Epstein-Barr Virus (EBV)-positive nasopharyngeal cancer (NPC) in humans. The drug VK-2019 was tested in a first-in-human clinical trial by a research team led by Wistar research associate professor Troy Messick, Ph.D., and Sta . . .